Cited by 168Menstrual Health and DisordersMenopause: Health Impacts and TreatmentsReproductive Health and Contraception

Efficacy of progesterone and progestogens in management of premenstrual syndrome: systematic review

Open access
Wyatt, Katrina, Dimmock, Paul, Jones, Peter, Obhrai, Manjit, O'Brien, Shaughn·2001·BMJ

Abstract

Objective: To evaluate the efficacy of progesterone and progestogens in the management of premenstrual syndrome. Design: Systematic review of published randomised, placebo controlled trials. Studies reviewed: 10 trials of progesterone therapy (531 women) and four trials of progestogen therapy (378 women). Main outcome measures: Proportion of women whose symptoms showed improvement with progesterone preparations (suppositories and oral micronised). Proportion of women whose symptoms showed improvement with progestogens. Secondary analysis of efficacy of progesterone and progestogens in managing physical and behavioural symptoms. Results: Overall standardised mean difference for all trials that assessed efficacy of progesterone (by both routes of administration) was −0.028 (95% confidence interval −0.017 to −0.040). The odds ratio was 1.05 (1.03 to 1.08) in favour of progesterone, indicating no clinically important difference between progesterone and placebo. For progestogens the overall standardised mean was −0.036 (−0.014 to −0.060), which corresponds to an odds ratio of 1.07 (1.03 to 1.11) showing a statistically, but not clinically, significant improvement for women taking progestogens. Conclusion: The evidence from these meta-analyses does not support the use of progesterone or progestogens in the management of premenstrual syndrome. What is already known on this topic: The premenstrual syndrome affects about 1.5 million women in the United Kingdom There are numerous treatment options, progesterone being one of the most strongly advocated Progesterone and progestogens are among the most widely prescribed treatments for premenstrual syndrome in the United Kingdom and the United States What this study adds: There is no evidence to support the claimed efficacy of progesterone in the management of premenstrual syndrome There is insufficient evidence to make a definitive statement about progestogens, but current evidence suggests that they are not likely to be effective

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/bmj.323.7316.776

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Displaying summary statistics by group is helpful, because it allows an assessment of the severity of the problem in the studies, which is not available from between-group results.

    “Displaying summary statistics by group is helpful, because it allows an assessment of the severity of the problem in the studies (such as level of depression symptoms), which is not available from between-group results (that is, effect estimates).137”

    From PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews (2021) · cites this paper as [137]

    The Statistical analysis section (page unavailable) describes a standardised mean difference as a dimensionless between-group effect estimate, supporting the distinction between effect estimates and group-level values. It does not say that displaying summary statistics by group helps readers assess the severity of symptoms in the studies. (LLM, conf=0.74)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

3 of the 55 references couldn’t be matched to a known paper.

Research works printed but not linked: 5

  1. [24]24. Richter MA, Haltvick R, Shapiro SS. Progesterone treatment of premen- strual syndrome. Curr Ther Res 1984;36:850.
  2. [31]31. Williams JGC, Martin AJ, Hulkenberg-Tromp A. Premenstrual syndrome in four European countries. Part 2. A double blind controlled study of dydrogesterone. Br J Sexual Med 1983;10:8-18.
  3. [39]39. Sampson GA, Heathcote PR, Wordsworth J, Prescott P, Hodgson A. Pre- menstrual syndrome. A double-blind cross-over study of treatment with dydrogesterone and placebo. Br J Psychiatry 1988;153:232-5.
  4. [44]44. Strecker JR. Treatment of premenstrual syndrome with retroprogester- one (Duphaston). Fortschr Med 1980;98:145-7.
  5. [46]46. Israel SL. Premenstrual tension. JAMA 1938;110:1721.

Cited by

Sorted by citations

Authors
Wyatt, K., Dimmock, P., Jones, P., Obhrai, M., & O'Brien, S.
Affiliations
University Hospitals of North Midlands NHS Trust (GB)
Venue
BMJ
Publisher
BMJ
Published
2001-10-06
Volume
323
Issue
7316
Pages
776
ISSN
  • 0007-1447 (ISSN-L)
  • 0959-8138
  • 1468-5833
OpenAlex
W2148616825
Cited by
168
References
55
Citations by year
2026: 2 · 2025: 2 · 2024: 6 · 2023: 5 · 2022: 4 · 2021: 4 · 2020: 1 · 2019: 2 · 2018: 4 · 2017: 3 · 2016: 6 · 2015: 4 · 2014: 6 · 2013: 10 · 2012: 14
FWCI
2.33
Type
journal article
Language
en
Open access
Locations
  • BMJ (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Menstrual Health and Disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Reproductive Health and Contraception
Keywords
premenstrual syndrome, progesterone, progestogens, symptom improvement, treatment efficacy, placebo comparison
MeSH terms
Female, Humans, Premenstrual Syndrome, Progestins, Progesterone, Odds Ratio, Randomized Controlled Trials as Topic, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review